Psilocybin-assisted therapy mediates psycho-social-spiritual change in cancer patients as assessed by the NIH-HEALS

Shnayder and colleagues frame the study around the substantial psycho-social and spiritual burden that can accompany a cancer diagnosis, including depression, anxiety, fear of dying, disconnection and loss of meaning. They note that traditional pharmacotherapies have limited and mixed efficacy for cancer-related distress, and that psychedelic-assisted therapies such as psilocybin have re-emerged as promising interventions. Earlier clinical research and recent trials suggest psilocybin can produce large improvements in cancer-related depression, anxiety and existential distress, but the mechanisms underlying psycho-spiritual change remain incompletely characterised. The investigators focus on the NIH-HEALS, a validated 35-item self-report instrument developed from interviews with patients facing severe or life‑threatening illness; factor analysis of the measure yielded three interrelated domains thought to underpin healing: Connection, Reflection & Introspection, and Trust & Acceptance. The present study was designed to evaluate change in NIH-HEALS scores in a sample of cancer patients with Major Depressive Disorder following a fixed 25 mg dose of psilocybin administered with preparatory and integration psychotherapy. The stated aim was to test whether psilocybin-assisted therapy produces measurable improvements on the NIH-HEALS and thereby provide evidence about the psychological elements that mediate psycho-social-spiritual change.

This was a Phase II, single-centre, fixed-dose, open‑label trial of psilocybin-assisted group therapy conducted at a cancer centre in Rockville, Maryland. Thirty participants were recruited over eight months by convenience sampling from the study site and referrals; written informed consent was obtained. Inclusion criteria were age ≥ 18 years, a DSM‑5 diagnosis of Major Depressive Disorder (single or recurrent) without psychotic features, a baseline Hamilton Depression Rating Scale (HAMD) score ≥ 18, and a malignant neoplasm (ICD‑10 C00–C97). Exclusion criteria followed standard psilocybin safety guidelines and included current or past psychotic disorder, bipolar disorder, borderline personality disorder, or significant suicide risk. Psychiatric medications were tapered per usual psychedelic research practice; participants continued oral cancer medications and no cancer procedures were performed during the study. Participants were treated in cohorts of 3–4 and completed eight visits across an 8‑week period. The therapeutic programme comprised individual and group preparatory sessions, simultaneous psilocybin administration in separate rooms with assigned therapists present, and individual and group integration sessions. The dosing visit (Visit 3) delivered 25 mg psilocybin; the in-session approach was non‑directive, used eyeshades and a music programme to promote an inner-directed experience, and therapists emphasised active listening and presence rather than interpretation or advice. Outcome measurement focused on the NIH‑HEALS, administered at baseline (Visit 2) and at week 1 (V5), week 3 (V6), and week 8 (V7) post‑treatment. The NIH‑HEALS is a 35‑item, 5‑point Likert measure (total score range 35–175) with three correlated factors: Connection, Reflection & Introspection, and Trust & Acceptance. For analysis, the investigators used mixed models for repeated measures to assess NIH‑HEALS scores over time, adjusting for baseline NIH‑HEALS, age (continuous) and gender (categorical). Post-hoc comparisons used Dunnett's method with baseline as the referent and analyses were conducted in SAS v9.4. The extracted text does not state whether an intention‑to‑treat principle was applied or give detailed sample‑level demographic breakdowns in the Methods section.

Thirty participants completed the intervention and follow‑up visits; detailed demographic tables are not clearly reported in the extracted methods text, although the Discussion later indicates the sample was predominantly Caucasian, female and employed. Adverse events during the psilocybin sessions were generally mild and transient, resolving by the end of the treatment session. Reported treatment‑related adverse events and their frequencies included headache (80%), nausea (40%), tearfulness (27%), anxiety (23%), euphoria (23%), fatigue (23%), and mild impairment of psychomotor functioning (10%). The investigators reported no notable laboratory abnormalities, ECG changes, or emergence of suicidality. On the primary psycho‑social‑spiritual outcome, total NIH‑HEALS scores increased following psilocybin‑assisted therapy. The extracted results report an average increase of 16.4 points in the NIH‑HEALS total score by week 8, and this change was statistically significant (p < 0.001). Within the subscales, the extracted text explicitly reports an increase in the Trust & Acceptance factor of 22.4% by week 8 (p < 0.001). The extracted Results section does not clearly report numerical change or significance for the Connection and Reflection & Introspection factors in the body text, though the study hypothesis and other parts of the document indicate these domains were of interest. Post‑hoc comparisons were adjusted for multiple testing using Dunnett's method with baseline as the referent comparison.

Shnayder and colleagues interpret the findings as evidence that psilocybin‑assisted therapy can facilitate psycho‑social‑spiritual growth in cancer patients, particularly by enhancing acceptance and trust, and by encouraging existential reflection and connection. They propose that therapeutic processes in preparation and integration sessions can be oriented to cultivate the NIH‑HEALS factors — for example, by emphasising connection, teaching mindfulness skills, promoting acceptance, and encouraging awareness of life's fragility. The authors situate these effects within a broader paradigm shift toward holistic treatment that recognises spiritual wellbeing alongside physical and psychological health. The investigators acknowledge several important limitations. The trial was open label and lacked a control arm, which limits causal inference. Use of a self‑report measure introduces potential social desirability or reporting bias. Sample size was relatively small and participant demographics were limited, reducing generalisability; specifically, the sample was predominantly Caucasian, female and employed. The authors recommend that future research include controlled designs and larger, more diverse samples to replicate and extend these findings. They conclude that the results deepen understanding of the psycho‑social‑spiritual changes associated with psilocybin therapy and support the relevance of the NIH‑HEALS factors for assessing such change.